Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2024 (Report Date: July 31, 2024)
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the cover page content.
Submitted Exhibits:
- Exhibit 99.1: Quarterly Activities/Appendix 4C Cash Flow Report
Investors must refer to Exhibit 99.1 for detailed financial data.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. The document serves primarily as a cover sheet incorporating the Quarterly Activities and Cash Flow Report by reference.
Guidance, Outlook, and Risks
Management Commentary: The registrant is identified as a "development stage enterprise," implying ongoing research and development activities rather than commercial revenue generation.
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Risks and Contingencies: No specific risks or contingencies are listed in the provided text.
Key Facts for Investor Verification
- Verify the specific cash flow figures and quarterly activities in Exhibit 99.1, as the cover page contains no numerical data.
- Confirm the company's status as a development stage enterprise and its implications for revenue timelines.
- Review the referenced Form S-8 and Form F-3 registration statements for details on equity offerings or employee benefit plans.
- Check the signature date of July 31, 2024, signed by Geoffrey P. Kempler, Chairman.